Summary

• Daratumumab binds to CD38 on red blood cells (RBCs) and results in a positive Indirect Antiglobulin Test (IAT; also known as Indirect Coombs test). Daratumumab-mediated positive IAT may persist for up to 6 months after the last daratumumab infusion. Daratumumab bound to RBCs masks detection of antibodies to minor antigens in the patient’s serum. The determination of a patient’s ABO and Rh blood type are not impacted.^1,2
  • Notify blood transfusion centers of this interference with serological testing and inform blood banks that a patient has received DARZALEX or DARZALEX FASPRO. Type and screen patients prior to starting DARZALEX or DARZALEX FASPRO.
• A brochure containing additional details for this interaction titled “Understanding Daratumumab Interference with Blood Compatibility Testing” can be accessed at the following weblink: https://www.janssenscience.com/media/attestation/general/JJD59161_AI_Brochure_HCP_11-6B_indd.pdf.